Biotechnology company Moderna, Inc. (NASDAQ: MRNA) Thursday reported net income for the third quarter of 2024, compared to a loss last year
Third-quarter revenues came in at $1.86 billion, compared to $1.83 billion in the prior-year periodThe company reported net profit of $13 million for Q3, compared to a loss of $3.63 billion in the same period last year On a per-share basis, Q3 earnings were $0.03, vs. a loss of $9.53 per share last yearNet product sales for the quarter were $1.8 billion, which is up 4% from the same period in 2023Q3 cost of sales was $514 million, including third-party royalties, unutilized manufacturing capacity, and inventory write-downsFor fiscal 2024, the company expects total product sales to be between $3.0 billion and $3.5 billionFull-year cost of sales is expected to be in the range of 40-45% of product salesCash, cash equivalents, and investments as of September 30, 2024, were $9.2 billion, vs. $10.8 billion last year
The post Earnings Summary: Moderna swings to profit in Q3 on modest revenue growth first appeared on AlphaStreet.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
